Searched for
BIOCON DIABETES DRUG
Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Biocon plans to launch generic Wegovy obesity drug in India by 2027, CEO saysBiocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027. This strategic ...
- Biocon drops plan to launch weight-loss drugs in China, executive saysBiocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense local competition...
- Biocon gets CDSCO nod for generic diabetes medicationBiocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Ty...
- Biocon shares in focus after CDSCO nod for diabetes drug LiraglutideBiocon shares are in focus as the company has received regulatory approval from the Central Drugs Standard Control Organisation for its dia...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management productBiocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio t...
- Biocon partners Biomm to commercialise diabetes drug in BrazilBiocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...
- Biocon Biologics launches Semglee, drug to control high blood sugar, in USTo encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98...
- Biocon Biologics, Voluntis tie up on digital therapeutics for people with diabetesInsulia provides automated insulin dose recommendations and coaching messages for people with diabetes, while enabling the healthcare team ...
- Biocon partners with Voluntis to develop digital therapeutics for diabetes patientsThe licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics o...
- Biocon gets US FDA nod to launch insulin glargineThe product branded as Semglee has an identical amino acid sequence to Sanofi’s Lantus® and is approved for the same indications. This is t...
- Biocon sees a sweet spot with its affordable insulin in USThe biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...
- NeoBiocon partners Novartis to launch diabetes drugs in UAENeoBiocon has received approvals from the Ministry of Health-UAE for marketing Jalra and Jalra-M in the country and the launch is scheduled...
- Biocon in insulin deal with US drug major Bristol-Myers SquibbBiocon has entered into a partnership for its oral insulin pill IN-105, giving BMS the option to exclusively develop and sell the product i...
- Biocon close to oral insulin deal with Bristol-Myers SquibbFour months after its partnership with Pfizer fell through, Biocon is now close to inking a deal with US-based biopharmaceuticals giant Bri...
Load More
